Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Transitional Cell Cancer of the Renal Pelvis and Ureter: early-phase trial registry
A small indexed set (4 trials) with no open enrollment listed right now.
Corpus placement: #4,115 of 28,707 conditions by registered trial count.
4 US clinical trials · none currently recruiting · #4,115 of 28,707 conditions by registered trial count
Transitional Cell Cancer of the Renal Pelvis and Ureter: 4 US clinical trials tracked, none currently recruiting.
Transitional Cell Cancer of the Renal Pelvis and Ureter is the subject of 4 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 0 are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most active sponsor is Eastern Cooperative Oncology Group, running 2 of these trials.
Enrollment posture brief
Registry condition transitional-cell-cancer-of-the-renal-pelvis-and-ureter
OPEN 0 | RECR 0% | LATE 0 | EARLY 4 | RANK #4115 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia (0% recruiting · 12 trials)
Transitional Cell Cancer of the Renal Pelvis and Ureter has no open enrollment in this registry pull (4 archived studies). Peers show how other volume-matched labels compare on open share. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Transitional Cell Cancer of the Renal Pelvis and Ureter on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Transitional Cell Cancer of the Renal Pelvis and Ureter is recruiting below its size-band peers.
0 of 4 indexed trials (0%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Indexed trials (enrollment closed)
4 total, page 1 of 1
Pemetrexed Disodium and Gemcitabine in Treating Patients With Advanced Cancer of the Urothelium
Eastern Cooperative Oncology Group
NCT00053209
S0031, ZD 1839 in Treating Patients With Advanced Cancer of the Urinary Tract
SWOG Cancer Research Network
NCT00014144
Docetaxel and Gemcitabine in Treating Patients With Progressive Regional or Metastatic Bladder Cancer
Eastern Cooperative Oncology Group
NCT00004223
R115777 in Treating Patients With Advanced Bladder Cancer
H. Lee Moffitt Cancer Center and Research Institute
NCT00006376
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 4 |
Top Sponsors
Named interventions
Most-linked intervention names on Transitional Cell Cancer of the Renal Pelvis and Ureter records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Transitional Cell Cancer of the Renal Pelvis and Ureter trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Transitional Cell Cancer of the Renal Pelvis and Ureter page
4 registered trials, 0 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- No Transitional Cell Cancer of the Renal Pelvis and Ureter trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Eastern Cooperative Oncology Group sponsors the most Transitional Cell Cancer of the Renal Pelvis and Ureter trials on record, review their full trial history before evaluating a specific study. See Eastern Cooperative Oncology Group's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Transitional Cell Cancer of the Renal Pelvis and Ureter condition card totals 4 registered trials; most-linked intervention gemcitabine hydrochloride; top US site state Florida. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.